The immune system is directly modulated by GRN and C9orf72, and MAPT clinical onset is influenced by levels of inflammation.34,40,41 Our data further highlight the neuroimmune axis in FTD, specifically expanding a possible role for B2 M in the clinical manifestations of TDP-43 and primary tauopathies. This evidence concerns the gene B2M and frontotemporal dementia.